Skip to main content
. 2021 Dec 1;6(6):100312. doi: 10.1016/j.esmoop.2021.100312

Figure 2.

Figure 2

Receiver operating characteristic curve (ROC) for prediction of progression to cabozantinib in mRCC patients, based on the assessment of cabozantinib Ctrough.

A threshold of 536.8 ng/ml for Ctrough had a 64.3% sensitivity and a 73.5% specificity to detect disease progression.